Time | Who | Title | Talk Title | |
Registration & Breakfast | 8:30-9:00 | |||
Welcome & Opening Remarks | 9:00-9:10 | Nadav Ahituv, PhD | Director, Institute for Human Genetics, University of California San Francisco | |
9:10-9:15 | Tippi MacKenzie, MD | Director, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco | ||
Keynote Speaker | 9:15-10:00 | Deepak Srivastava, MD | President, Gladstone Institutes; Professor, University of California San Francisco | Heart Disease: From Genetics to Therapeutics |
Break | 10:00-10:30 | |||
Gene Therapy | 10:30-10:50 | Steven Froelich, PhD | Director, Research and Development, BioMarin | Systematic discovery of neuronal cis-regulatory elements |
10:50-11:10 | Jennifer Hamilton, PhD | Co-Founder and Chief Executive Officer, Azalea Therapeutics | In vivo CAR-T cell Engineering via Cell-Selective Delivery and Genomic Locus-Specific Integration | |
11:10-11:30 | Mary McMahon, PhD | Director of Biology, ReviR Therapeutics | Rewriting the Message: Reprogramming mRNA by Targeted Splicing Modulation | |
11:30-11:50 | Aaron Tward, MD, PhD | Professor, Otolaryngology, University of California San Francisco; Associate Vice President, Gene Therapy, Eli Lilly | Gene therapy for hearing loss, present and future | |
11:50-12:20 | Panel Discussion | |||
Lunch & Career Panel | 12:20-1:35 | Beniamin Krupkin, PhD | Graduate Student, Bioengineering and Therapeutic Sciences, University of California San Francisco | The career panel during lunch with Peng He, Jennifer Hamilton, Marina Bershteyn, and Kanya Rajangam will take the form of a roundtable discussion. Beniamin Krupkin will lead the discussion with a few questions to get the ball rolling and from there we can take questions from trainees in the audience. This session is a great opportunity to learn more about diverse and impactful career paths in the biotech industry. |
Cell Therapy | 1:35-1:55 | Marina Bershteyn, PhD | Senior Director, Discovery Research Department, Neurona Therapeutics | Human GABAergic interneuron cell therapy for drug-resistant focal epilepsy |
1:55-2:15 | Kanya Rajangam, MD, PhD | President, Chief Medical Officer and Head of R&D, Senti Biosciences | Clinical Data from SENTI-202: First in Class Logic Gated Allogeneic CD33/FLT3 CAR NK cell therapy for R/R AML | |
2:15-2:35 | Deepak A. Lamba, MBBS, PhD | Distinguished Scientist and Director, Ophthalmology Discovery, Genentech | Retinal Cell Therapies: Successes and Challenges to the clinic | |
2:35-2:55 | Seyedeh Faranak Fattahi, PhD | Associate Professor, Cellular Molecular Pharmacology, University of California San Francisco | hPSC-based disease modeling and cell therapy for enteric neuropathies | |
2:55-3:25 | Panel Discussion | |||
Break | 3:25-3:55 | |||
Genomic Technologies | 3:55-4:15 | Aaron Wenger, PhD | Senior Director, Product Management, PacBio | More from every molecule |
4:15-4:35 | Siyuan Chen, PhD | Chief Technology Officer, Twist Bioscience | Breaking the Ceiling on DNA Synthesis | |
4:35-4:55 | Elena Cassidy, PhD Jesse Eaton, MS | Chief Executive Officer and Co-Founder, Omabit Chief Technology Officer and Co-Founder, Omabit | Omabit - Genomic AI for lifesciences | |
4:55-5:15 | Peng He, PhD | Assistant Professor, Pathology, University of California San Francisco | Integration for Discovery: Building a Unified Human Kidney Cell Atlas and Rethinking Batch Effects | |
5:15-5:45 | Panel Discussion | |||
Reception | 5:45-6:30 |